Article Text

Download PDFPDF
PTU-037 Predicting inflammatory pathology at capsule enteroscopy: what is the utility of a raised faecal calprotectin?
  1. C Parker,
  2. CA Lamb,
  3. M Robinson,
  4. JC Mansfield,
  5. M Gunn
  1. Gastroenterology, Royal Victoria Infirmary, Newcastle Upon Tyne, UK


Introduction Faecal Calprotectin (FCP) is a widely used biomarker of gastrointestinal (GI) mucosal inflammation. Many capsule enteroscopy (CE) services are receiving increased referrals of patients with abdominal symptoms combined with an elevated FCP (>50 µg/g) but normal gastroscopy, colonoscopy or radiology. There is little data on using FCP levels as a screening tool for selecting patients in whom CE will lead to a definitive diagnosis. Elevated FCP levels may indiscriminately drive investigations in endoscopy and imaging-negative patients who subsequently have normal findings at CE. We aimed to determine the incidence of inflammatory pathology on CE in patients with a raised FCP, and if a suitable concentration of the biomarker could be identified as a screening tool to avoid unnecessary CE.

Method A single centre retrospective review of The Newcastle upon Tyne Hospitals CE database was conducted (Feb 2012–Feb 2015). Patients with GI symptoms (abdominal pain, diarrhoea, bloating, vomiting, weight loss) and a raised FCP (>50 µg/g) were identified. Findings at CE considered to be inflammatory were: erythema, ulceration, erosions and fissuring.

Results 35 patients were identified with elevated FCP and GI symptoms. 45.7% (n = 16) had inflammation identified by CE and in 54.3% (n = 19) no inflammatory pathology was identified. The mean (+/-SE) FCP was higher in patients with evidence of inflammation at CE in comparison to those with no inflammation: 452.1 (95.8) µg/g vs. 206 (20.8) µg/g; p = 0.01. Stratifying patients according to FCP revealed that only 8.3% of patients (n = 1/12) with a FCP of 50–200 µg/g had inflammatory findings at CE. This rose to 58.3% of patients (n = 7/12) with a FCP of 201–300 µg/g, and 72.7% of patients (n = 8/11) with a FCP >300 µg/g. A threshold of 200 µg/g FCP revealed a sensitivity of 94.1% to predict inflammation at CE, with a specificity of 55.6%. This FCP threshold had a negative predictive value of 90.9%, and positive predictive value of 66.7% for CE inflammation.

Conclusion In this small retrospective analysis of a sub-group of patients referred for CE with a FCP of >50 μg/g the likelihood of identifying inflammatory pathology at CE increased with rising FCP concentrations above 200 μg/g. A threshold of 200 μg/g provided a high negative predictive value for CE inflammation and may be a useful screening tool to reduce the requirement for CE in select patient groups. This retrospective analysis should be confirmed in a larger prospective cohort.

Disclosure of interest None Declared.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.